文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

博茨瓦纳HIV感染与非HIV感染患者宫颈癌治疗启动延迟:一项观察性队列分析(2015-2019)

Delays in Cervical Cancer Treatment Initiation for Patients Living With or Without HIV in Botswana: An Observational Cohort Analysis (2015-2019).
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2024-03-10

该观察性队列研究前瞻性纳入2015至2019年博茨瓦纳556例局部晚期宫颈癌(IB2-IVB期)女性,评估诊断至治疗启动延迟对总生存的影响。早期患者延迟≥90天且病理诊断于2016-2019年者死亡风险降低(aHR 0.34),延迟≥90天且病理诊断早于2016年者死亡风险升高(aHR 5.67);晚期患者延迟≥120天且病理诊断于2018-2019年者死亡风险升高(aHR 1.98)。

要点

  • 早期宫颈癌患者治疗启动延迟长于晚期患者(P = .033)。
  • 早期患者延迟≥90天且2016-2019年诊断者死亡率降低(aHR 0.34,P < .001)。
  • 晚期患者延迟≥120天且2018-2019年诊断者死亡率升高(aHR 1.98,P = .025)。

核心结论

  • 在博茨瓦纳,宫颈癌治疗延迟常见,尤其见于居住地离治疗诊所较远和晚期患者。
  • 本文首次显示晚期宫颈癌治疗延迟与总生存恶化相关,强调需要干预帮助患者及时接受治疗。

研究设计与样本

  • 前瞻性观察性队列研究,2015至2019年纳入556例局部晚期宫颈癌(IB2-IVB期)女性,中位年龄47.9岁。
  • 386例(69.4%)为HIV感染女性,诊断时中位CD4计数448.0 cells/μL(IQR,283.0-647.5 cells/μL)。
  • 多数患者为2期(38.1%)或3期(34.5%)宫颈癌。
  • 评估诊断至治疗启动延迟30、60、90、120、150和180天及以上,采用多变量Cox比例风险回归(aHR)分析总生存相关因素。

主要发现

  • 早期患者治疗启动延迟长于晚期患者(P = .033)。
  • 早期患者延迟≥90天且病理诊断于2016-2019年者较<90天者死亡风险降低(aHR 0.34;P < .001)。
  • 早期患者延迟≥90天且病理诊断早于2016年者较<90天者死亡风险升高(aHR 5.67;P = .022)。
  • 晚期患者延迟≥120天且病理诊断于2018-2019年者较<120天者死亡风险升高(aHR 1.98;P = .025)。
  • 早期患者病理诊断于2016-2019年者较早于2016年者更可能发生延迟≥90天(OR 2.32;P = .043);晚期患者距治疗设施>100 km者较<100 km者更可能发生延迟≥120天(OR 2.83;P < .001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess delays in treatment initiation of chemoradiation or radiation alone for patients with advanced stage cervical cancer in Botswana. METHODS AND MATERIALS: Females with locally advanced cervical cancer (stages IB2-IVB) were prospectively enrolled in an observational cohort study from 2015 to 2019. We evaluated delays at 30, 60, 90, 120, 150, and 180 or greater days between the date of diagnosis and treatment initiation. Factors associated with overall survival were modeled with multivariable Cox proportional hazards regression (aHR). Associations between delays in cervical cancer treatment initiation were evaluated via univariable logistic regression. RESULTS: Among the 556 patients included (median age = 47.9 years), 386 (69.4%) were females living with HIV with a median CD4 count of 448.0 cells/μL (IQR, 283.0-647.5 cells/μL) at diagnosis. Most patients had stages 2 (38.1%) or 3 (34.5%) cervical cancer. Early-stage patients experienced longer delays in treatment initiation compared to late-stage patients (P = .033). Early-stage patients with delays ≥90 days and pathology diagnosis between 2016 and 2019 (aHR, 0.34; P < .001) versus <90 days had a decreased risk of mortality, and those with delays ≥90 days and pathology diagnosis before 2016 (aHR, 5.67; P = .022) versus <90 days had an increased risk of mortality. Late-stage patients with delays ≥120 days and pathology diagnosis between 2018 and 2019 (aHR, 1.98; P = .025) versus <120 days had an increased risk of mortality. Early-stage patients with pathology diagnosis between 2016 and 2019 (odds ratio, 2.32; P = .043) versus before 2016 were more likely to experience delays ≥90 days, and late-stage patients who traveled >100 km to the treatment facility (odds ratio, 2.83; P < .001) versus <100 km were more likely to experience delays ≥120 days. CONCLUSIONS: Delays in care are common in Botswana, particularly for those living farther from the treatment clinic and at advanced stages. This paper is among the first to show an association between treatment delays and worsened overall survival at advanced stages of cervical cancer, highlighting the need for interventions to help patients receive timely care in global settings.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. George J, Tuli S, Patel PP, et al. Delays in Cervical Cancer Treatment Initiation for Patients Living With or Without HIV in Botswana: An Observational Cohort Analysis (2015-2019). Int J Radiat Oncol Biol Phys. 2024. PMID: 38462016. doi:10.1016/j.ijrobp.2024.02.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。